Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) climbed nearly 2% in after-hours trading Monday after the U.S.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that the FDA has approved KALYDECO® (ivacaftor) for use in more than 600 people with cystic fibrosis (CF) …
J.P.
Gilead’s FDA-Approved Drug Still Faces an Uphill Battle in HCV Ring Gilead Sciences, Inc. (NASDAQ:GILD) just scored a green light from the FDA …
Many investors hope to win big on biotech stocks as shares can skyrocket when there is good news. Maxim analysts explain why there …
Valeant on Track to Meet $5 Billion Debt Reduction Commitments Ahead of Goal In a bullish research note previewing second quarter earnings from …
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) investors are overwhelmingly excited this afternoon after the drug maker announced positive data from Phase 1 and Phase 2 …
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have excited investors with key clinical moves forward for the firms, between VRTX’s double …
Following yesterday’s closing bell, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced positive Phase 3 results from two highly anticipated studies evaluating the tezacaftor and ivacaftor (Kalydeco) …
Overhang and political rhetoric have paved a tough road for biotech stocks in the past year. Investor concern has been rampant, but the …
